THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Atherosclerosis stabilization with PCSK-9 inhibition: An evolving concept for cardiovascular prevention

Citation for published version:

Robinson, JG, Heistad, DD & Fox, KAA 2015, 'Atherosclerosis stabilization with PCSK-9 inhibition: An evolving concept for cardiovascular prevention', *Atherosclerosis*, vol. 243, no. 2.
<https://doi.org/10.1016/j.atherosclerosis.2015.10.023>

Digital Object Identifier (DOI):

[10.1016/j.atherosclerosis.2015.10.023](https://doi.org/10.1016/j.atherosclerosis.2015.10.023)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Peer reviewed version

Published In:

Atherosclerosis

Publisher Rights Statement:

This is the author's peer-reviewed manuscript as accepted for publication.

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

Accepted Manuscript

Atherosclerosis stabilization with PCSK-9 inhibition: An evolving concept for cardiovascular prevention

Jennifer G. Robinson, MD, MPH, Professor, Donald D. Heistad, MD, Keith A.A. Fox, MB ChB, F Med Sci

PII: S0021-9150(15)30169-6

DOI: [10.1016/j.atherosclerosis.2015.10.023](https://doi.org/10.1016/j.atherosclerosis.2015.10.023)

Reference: ATH 14323

To appear in: *Atherosclerosis*

Received Date: 28 September 2015

Revised Date: 13 October 2015

Accepted Date: 20 October 2015

Please cite this article as: Robinson JG, Heistad DD, Fox KAA, Atherosclerosis stabilization with PCSK-9 inhibition: An evolving concept for cardiovascular prevention, *Atherosclerosis* (2015), doi: 10.1016/j.atherosclerosis.2015.10.023.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Atherosclerosis stabilization with PCSK-9 inhibition: An evolving concept for cardiovascular prevention

Jennifer G Robinson, MD, MPH

Donald D. Heistad, MD

University of Iowa

Keith A A Fox, MB ChB, F Med Sci

Edinburgh University

Corresponding author

Jennifer G. Robinson, MD, MPH
Professor, Departments of Epidemiology & Medicine
Director, Prevention Intervention Center
Department of Epidemiology
College of Public Health
University of Iowa
145 N Riverside Drive S455 CPHB
Iowa City, IA 52242-2007
USA
Office 319.384.1563
Assistant 319.384.1540
Fax 319.384.4155
Email: jennifer-g-robinson@uiowa.edu

Words: 1904

Figures: 1

Tables: 1

References: 34

Relationships with industry:

Dr. Robinson serves as the Principal Investigator for clinical trials of PCSK-9 monoclonal antibodies and CETP inhibitors (Amgen, Merck, Pfizer, Regeneron/Sanofi). She serves as a consultant for manufacturers of PCSK-9 monoclonal antibodies and CETP inhibitors (Amgen, Eli Lilly, Merck, Pfizer, Regeneron/Sanofi).

Dr. Heistad has no relationships with industry to report. Original research supported by NIH grant HL-062984.

Dr. Fox serves as a consultant for manufacturers of PCSK-9 monoclonal antibodies (Regeneron/Sanofi and Eli Lilly), and Bayer/Janssen, Glaxo Smith-Kline.

Key words

PCSK-9 inhibitor

Plaque stabilization

Regression

Cardiovascular prevention

Statin

Abstract

Monoclonal antibodies (mAbs) to proprotein convertase subtilisin/kexin type 9 (PCSK-9) can further lower LDL-C by $\geq 60\%$ in statin-treated patients. Preliminary data suggest they may reduce cardiovascular (CVD) events. Ongoing PCSK-9 mAb cardiovascular outcomes trials could provide the opportunity to determine whether a “legacy effect” similar to that observed for statins will occur over the post-trial observation period. We hypothesize these trials could demonstrate that (1) very aggressive LDL-C lowering with PCSK-9 mAbs added to background statin therapy will induce extensive atherosclerosis stabilization and regression in the large majority of treated patients, and (2) continued maintenance therapy with high intensity statin therapy (with or without ezetimibe) should then inhibit new plaque formation, with a long-term prevention of CVD events. The necessity of expensive lifetime treatment with PCSK-9 inhibitors could then be avoided in all but a small subset of patients who could benefit from longer treatment.

Words: 145

Statins reduce the risk of cardiovascular events in patients with clinical atherosclerotic cardiovascular disease but many patients remain at increased risk of recurrent events.(1). Monoclonal antibodies (mAbs) to proprotein convertase subtilisin/kexin type 9 (PCSK-9 can further lower LDL-C by 60% or more when added to background statin therapy, and preliminary data from shorter-term follow-up of efficacy/safety trials suggest they further reduce recurrent CVD events in high risk patients by about 50% over a treatment period of 11-18 months.(2, 3) While PCSK-9 mAbs hold the promise of great clinical benefit for a significant number of patients, they are very expensive drugs (approximately US\$14,000 per year)(4). We propose testing a new paradigm for cardiovascular prevention that moves away from lifetime preventive therapy and capitalizes on a substantial impact on a legacy effect cardiovascular events over the long-term, thereby minimizing the expenditures for these new drugs while capturing the benefit . Extended follow-up of the large ongoing cardiovascular outcomes trials of PCSK-9 mAbs provide just such an opportunity. (5-8) We hypothesize that (1) very aggressive LDL-C lowering with PCSK-9 mAbs added to background statin therapy during the trials will promote atherosclerosis stabilization and lesion regression in treated patients, and (2) continued maintenance therapy with high intensity statin therapy (with or without ezetimibe) should inhibit new plaque formation, with long-term prevention of CVD events. Therefore, it may be possible for shorter-term PCSK-9 inhibitor therapy could be sufficient for the large majority of patients, and the necessity of lifetime treatment with PCSK-9 inhibitors avoided in all but a small subset of patients.

Legacy effects

Meta-analysis of post-trial follow-up of the statin trials found long-term reductions in the relative risk of recurrent CVD events after discontinuation of statin therapy, with a magnitude of relative risk reduction similar to that observed in the active treatment period of the trial in primary and

secondary prevention trials.(9, 10) This may suggest persistent benefit from statin-induced plaque stabilization and reduction in plaque volume through regression, a phenomenon observed in the coronary intravascular ultrasound trials. This concept raises the possibility that more marked LDL-C reductions with PCSK-9 mAbs may have an even greater impact on plaque burden and disease stabilization and hence exhibit an even more profound “legacy effect”. In support of this hypothesis, meta-analyses have found that statin therapy reduces fibrous plaque volume and improves vascular remodeling by virtual histology ultrasound, with plaque regression occurring after an average 19 months of treatment.(11, 12) Meta-analysis of high intensity statin coronary intravascular ultrasound trials has found that the lower the achieved LDL-C levels, the greater the magnitude of plaque regression down to an LDL-C level of 15 mg/dl (**Figure 1**). (13) Optical coherence tomography reveals more stable plaque features in patients with very low on-treatment LDL-C levels.(14) Other These vascular changes are consistent with the greater reduction in CVD events observed when progressively lower levels of LDL-C levels to <50 mg/dl were achieved in statin CVD outcomes trials of 2-6 years duration.(15)

PCSK-9 mAbs

Notably, when added to maximal statin or other lipid-lowering therapy in high risk patients, PCSK-9 mAbs lower LDL-C an additional 60-65% and result in achieved average LDL-C levels of 35-50 mg/dl.(2, 3, 16) Over 40% of patients on high intensity statins achieved persistent reductions in LDL-C <25 mg/dl with the addition of a PCSK-9 mAb.(16)

In preliminary analyses of Phase 3 efficacy/safety trials of the PCSK-9 mAbs, alirocumab and evolocumab, these remarkable reductions in LDL-C appear to have resulted in CVD event reductions of approximately 50% over a period of 11-18 months.(2, 3) Both drugs reduced LDL-C by an additional 60% when added to background therapy. An early separation of the event curves was observed in both studies. A meta-analysis of events reported in 24 phase 2 and 3 efficacy/safety trials of evolocumab and

alirocumab (n=10,159) found a preliminary suggestion that PCSK-9 mAbs may also reduce cardiovascular and total mortality.(17)

The further reduction in CVD events when PCSK-9 mAbs are added to statin therapy is at least the magnitude expected from the degree of LDL-C lowering when compared to the statin trials. The Cholesterol Treatment Trialists' meta-analysis of statin trials found that each 39 mg/dl (1 mmol/L) reduction in LDL-C was associated with a 21% reduction in major cardiovascular events.(18) The average 70 mg/dl reduction in LDL-C reduced cardiovascular events by 50% in the PCSK-9 trials. Thus, it appears the cardiovascular risk reduction from PCSK-9 inhibitors is at least as much as expected from a similar magnitude of LDL-C reduction from statins (eg, a 38% relative risk reduction in cardiovascular events expected for a 70 mg/dl reduction in LDL-C). Ezetimibe is another LDL-C lowering drug shown to modestly reduce cardiovascular events in relationship to the modest magnitude of LDL-C lowering.(19) Along with data from a trial of intestinal bypass surgery and diet, this suggests statin's pleiotropic effects are unlikely to be contributing additional risk reduction benefit(20), and that LDL-C lowering with PCSK-9 mAbs is likely to have analogous effects on plaque stabilization and regression as a function of the magnitude of LDL-C lowering. On the other hand, whether the anti-inflammatory effects of statins are mediated by LDL-C lowering, and if these same anti-inflammatory effects occur with PCSK-9 mAbs remains to be determined. (21) No cardiovascular imaging trials have yet been completed with PCSK-9 mAbs, although a coronary intravascular ultrasound trial is underway with evolocumab.(22) However, based on the reduction in cardiovascular outcomes observed to date, it appears that PCSK-9 mAbs are likely to result in further plaque regression and stabilization in statin-treated patients.

Further plaque stabilization and regression with the addition of a PCSK-9 inhibitor to statin therapy is supported by animal data that have found more plaque regression, along with a greater proportion of stable plaque, occurs from the addition reduction in LDL-C.(23) The PCSK-9 inhibitor alicumab has been shown to reduce apolipoprotein B-containing lipoproteins, atherosclerotic lesion

size and severity, and to increase lesion stability in APOE*3Leiden.CETP mice fed a Western diet. (24)

The distribution of plaque was reversed in alirocumab+atorvastatin treated animals, with about 75% of lesions in the undiseased state compared to about 75% in the severe state in untreated animals.

Alirocumab improved plaque morphology by reducing monocyte recruitment and content of macrophages and necrotic core, and increasing smooth muscle and collagen content. These effects occurred after 18 weeks of alirocumab treatment and were enhanced when added to atorvastatin therapy, with an 89% reduction in lesion size in that group. Lesion area correlated well with cholesterol-lowering. These findings are consistent with animal models where atherosclerotic changes resulting from a high cholesterol diet regress when animals are returned to a standard diet.(23)

Proving the hypothesis

Continued follow-up of study participants once the ongoing PCSK-9 mAb cardiovascular outcomes trials end will provide a critical opportunity to test a new paradigm for cholesterol treatment: Is there a legacy effect after a period of profound LDL-C lowering? Planned post-trial follow-up can document whether shorter term therapy (2-4 years) with PCSK-9 mAbs will result in a long term reduction in cardiovascular events once treatment is stopped and patients are maintained long-term on maximal statin therapy. It is unlikely there will be large-scale cross-over to PCSK-9 mAbs after the end of the trial given the likelihood of high cost and restrictive access, at least over the nearer term, providing the opportunity for a natural experiment if post-trial follow-up is through a planned long-term observational program. Such follow-up would also provide the opportunity to collect biomarkers or perform imaging that could be used to identify patients at high risk of another cardiovascular event who could benefit from continued PCSK-9 treatment. In several countries, record linkage provides a cost-effective method of obtaining robust mortality data over the very long-term.(25) Other methods of regular follow-up have been successful for large epidemiologic studies and registries (26, 27). Planned

post-trial follow-up would also facilitate a randomized trial of biomarker or imaging-guided treatment to evaluate whether continued PCSK-9 mAb treatment will further reduce cardiovascular risk in study participants who are identified as being at persistently high risk of recurrent events at the end of the trial through clinical characteristics, biomarkers, or imaging evidence of unstable plaque. ¹⁸F-NaF PET-CT has recently been identified as a particularly promising noninvasive measure of unstable plaque.(28)

After the end of the PCSK-9 outcomes trial treatment period, participants are very likely to continue maximal statin or statin/ezetimibe therapy as the standard of care therapy. Prevention of new plaque formation is the second important component of the new treatment paradigm. Epidemiologic evidence suggests atherosclerotic lesions are unlikely to form when non-HDL-C levels are <125 mg/dl (corresponding to LDL-C <95 mg/dl) through middle-adulthood.(29) Whether this same phenomenon occurs in those with an extensive burden of atherosclerosis such as those enrolled in the PCSK-9 mAb trials remains to be determined. In addition, longer-term follow-up will reveal whether there is an LDL-C level that results in prevention of new lesion formation.

Animal studies may be helpful in supporting the new paradigm of time-limited but very intensive LDL-C lowering. Studies evaluating plaque morphology after the discontinuation of aggressive lipid-lowering therapy while maintained on background statin therapy will be an important area for future investigation.(23) To our knowledge, such trials have not been performed to date.

Other drugs in development

This strategy could be investigated for other lipid-modifying agents under development, such as cholesteryl ester transfer protein (CETP) inhibitors which have been shown to have similar effects to PCSK-9 mAbs plaque regression in animal models which re mediated by non-HDL-C lowering. (30) In humans, a similar relationship with achieved non-HDL-C level and a reduction in cardiovascular events was observed in the statin trials.(15) If shown to reduce cardiovascular events in ongoing trials,(31, 32)

and with long-term follow-up, these drugs could be used in a similar fashion as proposed for PCSK-9 mAbs.

Clinical implications

We have proposed a new paradigm for cardiovascular prevention that could be supported by data from ongoing cardiovascular outcomes trials of PCSK-9 mAbs. After an initial period of atherosclerosis stabilization through shorter-term, very aggressive LDL reduction during the trial, long-term post-trial follow-up may document persistent risk reductions after the PCSK-9 mAb therapy has been discontinued (a “legacy effect”), while the patient remains on maintenance statin therapy. These data may provide a potent, more cost-effective strategy for long-term cardiovascular risk reduction since the cost of 2-4 years of PCSK-9 inhibitor therapy (depending on the length of the randomized, controlled trial treatment period) could then be amortized over periods of time as long as 10 years off the PCSK-9 mAb. For example, if the preliminary results of the PCSK-9 efficacy/safety trials are substantiated, and a 50% relative risk reduction during the trial is sustained off the PCSK-9 mAb over a period of up to 10 years, this could result in marked reductions in risk for patients across the spectrum of cardiovascular risk. As shown in **Table 1**, a consistent 50% reduction in the relative risk of a cardiovascular event would result in a number-needed-to-treat of 10 or less to prevent one event after 10 years for patients with 20% 10-year cardiovascular risk, such as those with clinical ASCVD on a statin.⁽³³⁾ This approach could also be evaluated in younger patients with heterozygous familial hypercholesterolemia, where a period of intensive plaque regression and stabilization might be followed by less intensive therapy to maintain LDL-C levels of approximately 100 mg/dl. Therefore, it is possible that the cost of expensive drugs used for a limited period (2-3 years) could be averaged over a longer period, and prove cost-effective.

References

1. Cholesterol Treatment Trialists Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. *Lancet*. 2010;376:1670-81.
2. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, El Shahawy M, Koren MJ, Lepor NE, Lorenzato C, Pordy R, Chaudhari U, Kastelein JJP. Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events. *New England Journal of Medicine*. 2015;372(16):1489-99. doi: doi:10.1056/NEJMoa1501031. PubMed PMID: 25773378.
3. Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, Wasserman SM, Scott R, Koren MJ, Stein EA. Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events. *New England Journal of Medicine*. 2015;372(16):1500-9. doi: doi:10.1056/NEJMoa1500858. PubMed PMID: 25773607.
4. Regeneron Pharmaceuticals Inc, Sanofi Aventis. Regeneron and Sanofi Announce FDA Approval of Praluent® (alirocumab) Injection, the First PCSK9 Inhibitor in the U.S., for the Treatment of High LDL Cholesterol in Adult Patients 2015 [updated July 24, 2015; cited July 24, 2015]. Available from: www.prnewswire.com/news-releases/regeneron-and-sanofi-announce-fda-approval-of-praluent-alirocumab-injection-the-first-pcsk9-inhibitor-in-the-us-for-the-treatment-of-high-ldl-cholesterol-in-adult-patients-300118572.html.
5. Amgen. Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER). ClinicalTrials.gov Identifier: NCT01764633 2014 [updated December 12, 2014; cited April 3, 2015]. Available from: <https://clinicaltrials.gov/ct2/show/NCT01764633?term=fourier+amgen&rank=1>.
6. Sanofi/Regeneron. ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727). ClinicalTrials.gov Identifier: NCT01663402 2015 [updated March 26, 2015; cited April 3, 2015]. Available from: <https://clinicaltrials.gov/ct2/show/NCT01663402?term=odyssey+outcomes&rank=1>.
7. Pfizer. The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects (SPIRE-2). ClinicalTrials.gov Identifier: NCT01975389 2015 [updated March 13, 2015; cited April 3, 2015]. Available from: <https://clinicaltrials.gov/ct2/show/NCT01975389?term=pfizer+SPIRE&rank=3>.
8. Pfizer. The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects (SPIRE-1). ClinicalTrials.gov Identifier: NCT01975376 2015 [updated March 18, 2015; cited April 3, 2015]. Available from: <https://clinicaltrials.gov/ct2/show/NCT01975376?term=pfizer+SPIRE&rank=4>.
9. Lv H-I, Jin D-m, Liu M, Liu Y-m, Wang J-f, Geng D-f. Long-term efficacy and safety of statin treatment beyond six years: A meta-analysis of randomized controlled trials with extended follow-up. *Pharmacological Research*. 2014;81(0):64-73. doi: <http://dx.doi.org/10.1016/j.phrs.2014.02.006>.
10. Heart Protection Study Collaborative G. Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20 536 high-risk individuals: a randomised controlled trial. *Lancet*. 2011;378:2013-20. doi: 10.1016/s0140-6736(11)61125-2.
11. Noyes AM, Thompson PD. A systematic review of the time course of atherosclerotic plaque regression. *Atherosclerosis*. 2014;234:75-84. doi: <http://dx.doi.org/10.1016/j.atherosclerosis.2014.02.007>.
12. Banach M, Serban C, Sahebkar A, Mikhailidis D, Ursoniu S, Ray K, Rysz J, Toth P, Muntner P, Mosteoru S, Garcia-Garcia H, Hovingh G, Kastelein J, Serruys P, Lipid, Group BPM-aC. Impact of statin therapy on coronary plaque composition: a systematic review and meta-analysis of virtual histology

intravascular ultrasound studies. *BMC Medicine*. 2015;13(1):229. PubMed PMID: doi:10.1186/s12916-015-0459-4.

13. Puri R, Nissen SE, Shao M, Uno K, Kataoka Y, Kapadia SR, Tuzcu EM, Nicholls SJ. Impact of Baseline Lipoprotein and C-Reactive Protein Levels on Coronary Atheroma Regression Following High-Intensity Statin Therapy. *Am J Cardiol*. 2014;114:1465-72. doi: <http://dx.doi.org/10.1016/j.amjcard.2014.08.009>.
14. Kataoka Y, Hammad M, Puri R, Duggal B, Uno K, Kapadia SR, Murat Tuzcu E, Nissen SE, Nicholls SJ. Plaque microstructures in patients with coronary artery disease who achieved very low low-density lipoprotein cholesterol levels. *Atherosclerosis*. 2015;242(2):490-5. doi: <http://dx.doi.org/10.1016/j.atherosclerosis.2015.08.005>.
15. Boekholdt SM, Hovingh GK, Mora S, Arsenault BJ, Amarencu P, Pedersen TR, LaRosa JC, Waters DD, DeMicco DA, Simes RJ, Keech AC, Colquhoun D, Hitman GA, Betteridge DJ, Clearfield MB, Downs JR, Colhoun HM, Gotto Jr AM, Ridker PM, Grundy SM, Kastelein JJP. Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events: A Meta-Analysis of Statin Trials. *J Am Coll Cardiol*. 2014;64:485-94. doi: <http://dx.doi.org/10.1016/j.jacc.2014.02.615>.
16. Robinson JG, Nedergaard BS, Rogers WJ, et al. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on ldl-c lowering in patients with hypercholesterolemia: The LAPLACE-2 randomized clinical trial. *JAMA*. 2014;311:1870-82. doi: 10.1001/jama.2014.4030.
17. Navarese EP, Kołodziejczak M, Schulze V, Gurbel PA, Tantry U, Lin Y, Brockmeyer M, Kandzari DE, Kubica JM, D'Agostino Sr RB, Kubica J, Volpe M, Agewall S, Kereiakes DJ, Kelm M. Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis. *Annals of Internal Medicine*. 2015;N/A(N/A):N/A-N/A. doi: 10.7326/M14-2957.
18. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. *Lancet* 2005;366:1267-78.
19. Cannon C, On behalf of the IMPROVE-IT study group. IMPROVE-IT Trial: A Comparison of Ezetimibe/Simvastatin versus Simvastatin Monotherapy on Cardiovascular Outcomes After Acute Coronary Syndrome; Presented at the American Heart Association Scientific Sessions, November 17, 2014. *Circulation* 2014 130:2105-26. doi: 10.1161/01.cir.0000457464.79076.2c
20. Robinson JG, Smith B, Maheshwari N, Schrott H. Pleiotropic effects of statins: Benefit beyond cholesterol reduction? A meta-regression analysis *J Am Coll Cardiol*. 2005 46:1855-62.
21. Robinson JG. Models for describing relations among the various statin drugs, low-density lipoprotein cholesterol lowering, pleiotropic effects, and cardiovascular risk. *Am J Cardiol*. 2008;101:1009-15.
22. Amgen. GLObal Assessment of Plaque reGression With a PCSK9 antibody as Measured by intraVascular Ultrasound (GLAGOV) NCT01813422 2015 [updated March 17, 2015; cited April 1, 2015]. Available from: <https://clinicaltrials.gov/ct2/show/NCT01813422>.
23. Williams KJ, Feig JE, Fisher EA. Rapid regression of atherosclerosis: Insights from the clinical and experimental literature. *Nat Clin Pract Cardiovasc Med*. 2008;5:91-102.
24. Kühnast S, van der Hoorn JWA, Pieterman EJ, van den Hoek AM, Sasiela WJ, Gusarova V, Peyman A, Schäfer H-L, Schwahn U, Jukema JW, Princen HMG. Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin. *Journal of Lipid Research*. 2014;55(10):2103-12. doi: 10.1194/jlr.M051326.
25. Packard C, Ford I, Murray HM, McCowan C. Lifetime Clinical and Economic Benefits of Statin-Based LDL Lowering in the 20-Year Followup of the West of Scotland Coronary Prevention Study. *Circulation*. 2014 130:2105-26. Epub

doi: doi: 10.1161/01.cir.0000457464.79076.2c

26. Hlatky MA, Douglas PS, Cook NL, Wells B, Benjamin EJ, Dickersin K, Goff DC, Hirsch AT, Hylek EM, Peterson ED, Roger VL, Selby JV, Udelson JE, Lauer MS. Future Directions for Cardiovascular Disease Comparative Effectiveness Research: Report of a Workshop Sponsored by the National Heart, Lung, and Blood Institute. *Journal of the American College of Cardiology*. 2012;60(7):569-80. doi: 10.1016/j.jacc.2011.12.057.
27. Hlatky MA, Ray RM, Burwen DR, Margolis KL, Johnson KC, Kucharska-Newton A, Manson JE, Robinson JG, Safford MM, Allison M, Assimes TL, Bavry AA, Berger J, Cooper-DeHoff RM, Heckbert SR, Li W, Liu S, Martin LW, Perez MV, Tindle HA, Winkelmayer WC, Stefanick ML. Use of Medicare Data to Identify Coronary Heart Disease Outcomes in the Women's Health Initiative. *Circulation: Cardiovascular Quality and Outcomes*. 2014;7(1):157-62. doi: 10.1161/circoutcomes.113.000373.
28. Joshi NV, Vesey AT, Williams MC, Shah ASV, Calvert PA, Craighead FHM, Yeoh SE, Wallace W, Salter D, Fletcher AM, van Beek EJ, Flapan AD, Uren NG, Behan MWH, Cruden NLM, Mills NL, Fox KAA, Rudd JHF, Dweck MR, Newby DE. 18F-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques: a prospective clinical trial. *Lancet*. 2014;383(9918):705-13. doi: [http://dx.doi.org/10.1016/S0140-6736\(13\)61754-7](http://dx.doi.org/10.1016/S0140-6736(13)61754-7).
29. Navar-Boggan AM, Peterson ED, D'Agostino RB, Neely B, Sniderman AD, Pencina MJ. Hyperlipidemia in Early Adulthood Increases Long-Term Risk of Coronary Heart Disease. *Circulation*. 2015. doi: 10.1161/circulationaha.114.012477.
30. Kühnast S, van der Tuin SJL, van der Hoorn JWA, van Klinken JB, Simic B, Pieterman E, Havekes LM, Landmesser U, Lüscher TF, Willems van Dijk K, Rensen PCN, Jukema JW, Princen HMG. Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin. *Eur Heart J*. 2015;36(1):39-50. doi: 10.1093/eurheartj/ehu319.
31. University of Oxford, Merck. REVEAL: Randomized Evaluation of the Effects of Anacetrapib Through Lipid-modification. ClinicalTrials.gov Identifier: NCT01252953 2014 [updated April 16, 2014; cited April 3, 2015]. Available from: <https://clinicaltrials.gov/ct2/show/NCT01252953?term=reveal+merck&rank=1>.
32. Eli Lilly and Company. A Study of Evacetrapib in High-Risk Vascular Disease (ACCELERATE). ClinicalTrials.gov Identifier: NCT01687998 2015 [updated February 23, 2015; cited April 3, 2015]. Available from: <https://clinicaltrials.gov/ct2/show/NCT01687998?term=evacetrapib+lilly&rank=19>.
33. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart J-C, Gotto AM, Greten H, Kastelein JJP, Shepherd J, Wenger NK, the Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. *N Engl J Med*. 2005;352:1425-35.
34. Robinson J, Stone N. The 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk: A new paradigm supported by more evidence. *Eur Heart J*. 2015 36:2110-8. doi: doi:10.1093/eurheartj/ehv182.

Figure 1. Change in percent (PAV) and total atheroma volume (TAV) by coronary intravascular ultrasound by achieved mean LDL-C level on treatment with 18-24 months of rosuvastatin 40 mg or atorvastatin 80 mg (n=1881). Adapted from Puri R, Nissen SE, et al. Am J Cardiol 2014; 114: 1465-1472.(13)

Table 1. Number-needed to treat to prevent 1 CVD event. As an example, patients with 20% 10-year hard cardiovascular risk would include those in the Treating-to-New-Targets trial, where the 5-year risk of patients with coronary heart disease were treated with atorvastatin 10 or 80 mg was 9-11%.(33)

Adapted from Robinson J, Stone N. The 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk: A new paradigm supported by more evidence. From Robinson JG, Stone NJ. Eur Heart J 2015 Online ahead of print May 20, 2015:doi: 10.1093/eurheartj/ehv182.(34)

5-year CVD rate	5-year NNT						10-year CVD rate	10-year NNT					
	LDL-C reduction (mg/dl)							LDL-C reduction (mg/dl)					
	18	26	35	44	61			18	26	35	44	61	
	Relative risk reduction							Relative risk reduction					
	10%	15%	20%	25%	35%	50%		10%	15%	20%	25%	35%	50%
25%	40	27	20	16	11	8	50%	20	13	10	8	6	4
20%	50	33	25	20	14	10	40%	25	17	13	10	7	5
15%	67	44	33	27	19	13	30%	33	22	17	13	10	7
10%	100	67	50	40	29	20	20%	50	33	25	20	14	10
5%	200	133	100	80	57	40	10%	100	67	50	40	29	20